Abstract
We have greatly enjoyed reading the article by Gurgun and coworkers which aimed to evaluate the impact of 12-week fluvastatin treatment on the inflammatory cytokines and left ventricular (LV) performance markers in patients with chronic heart failure who also had hyperlipidemia (CHF) [1]. The authors observed that fluvastatin improved cardiac functions and the clinical symptoms in CHF patients both nonischemic and ischemic etiology. They concluded that the beneficial effect of fluvastatin which might be secondary to inflammatory modulation was more marked in patients with ischemic etiology [1].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
